Literature DB >> 121890

Chemotherapy in the management of ovarian carcinoma: a review.

J S Malpas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 121890      PMCID： PMC1436877     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  19 in total

1.  Management of ovarian carcinoma. Current concepts and future prospects.

Authors:  J S Tobias; C T Griffiths
Journal:  N Engl J Med       Date:  1976-04-15       Impact factor: 91.245

2.  Understanding the problem of understaging in ovarian cancer.

Authors:  P Rubin
Journal:  Semin Oncol       Date:  1975-09       Impact factor: 4.929

3.  Treatment of epithelial carcinoma of the ovary: operation, irradiation, and chemotherapy.

Authors:  R S Bush; W E Allt; F A Beale; H Bean; J F Pringle; J Sturgeon
Journal:  Am J Obstet Gynecol       Date:  1977-04-01       Impact factor: 8.661

Review 4.  Chemotherapy of ovarian cancer: past and present.

Authors:  R C Young
Journal:  Semin Oncol       Date:  1975-09       Impact factor: 4.929

5.  Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy.

Authors:  J P Smith; F N Rutledge; L Delclos
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

Review 6.  Perspectives on research in gynecologic oncology.

Authors:  V T DeVita; T H Wasserman; R C Young; S K Carter
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

7.  Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.

Authors:  E Wiltshaw; T Kroner
Journal:  Cancer Treat Rep       Date:  1976-01

8.  Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.

Authors:  S Piver; J J Barlow; W S Chung; F T Lee; V Vongtama
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

9.  Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.

Authors:  R C Young; B A Chabner; S P Hubbard; G P Canellos; V T DeVita
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

10.  Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.

Authors:  H W Bruckner; L H Ratner; C J Cohen; R Wallach; B Kabakow; E M Greenspan; J F Holland
Journal:  Cancer Treat Rep       Date:  1978-07
View more
  3 in total

1.  The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Authors:  Zhu Yuan; Kang Cao; Chao Lin; Lei Li; Huan-yi Liu; Xin-yu Zhao; Lei Liu; Hong-xin Deng; Jiong Li; Chun-lai Nie; Yu-quan Wei
Journal:  Mol Med       Date:  2011-08-19       Impact factor: 6.354

2.  Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas.

Authors:  Carlos S Moreno; Lilya Matyunina; Erin B Dickerson; Nina Schubert; Nathan J Bowen; Sanjay Logani; Benedict B Benigno; John F McDonald
Journal:  PLoS One       Date:  2007-05-16       Impact factor: 3.240

Review 3.  Predicting Response to Anthracyclines in Ovarian Cancer.

Authors:  Annamaria Ferrero; Martina Borghese; Stefano Restaino; Andrea Puppo; Giuseppe Vizzielli; Nicoletta Biglia
Journal:  Int J Environ Res Public Health       Date:  2022-04-02       Impact factor: 3.390
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.